Bär & Karrer Advises the Managers in the Rights Offering of Kuros Biosciences

On 18 December 2018, Kuros Biosciences, a life science company focusing on the development and marketing of orthobiologics, completed a capital increase by way of a rights offering to its shareholders in the amount of approximately CHF 16.1 million. 34.6% of the shareholders of Kuros Biosciences exercised their subscription rights in the rights offering. The remaining new shares not subscribed were placed in the market. The offer price was set at CHF 2.50 per share.
Mirabaud, Octavian and Helvetische Bank acted as Managers.

Bär & Karrer acted as legal adviser to the Managers in this transaction. The team included Thomas U. Reutter, Alexander von Jeinsen, Carlo Hunter and Manuela Cassano (all Capital Markets) as well as Christoph Suter and Cyrill Diefenbacher (both Tax).